Logo

RxGen Gets $1.1M SBIR Grant to Study Genomic Markers of Parkinson s Disease

Dec 08, 2004

NEW YORK, Dec. 8 (GenomeWeb News) - RxGen has received a $1.1 million Fast Track SBIR grant to identify genomic markers of Parkinson's disease.

 

The New Haven, Conn.-based firm will use its PrimaTox predictive toxicology technology program to study toxins such as rotenone, tetrahydroisoquinolone, dithiocarbamate, and Paraquat, which have been implicated as possible environmental causes of Parkinson's disease.

 

RxGen said it would profile in vivo brain RNA expression patterns following exposure to the toxins in an attempt to uncover critical pathways of injury and neuroprotection specific to dopaminergic neurons.

Breaking News
The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.